Anesthesia and analgesia
-
Anesthesia and analgesia · May 1998
Randomized Controlled Trial Clinical TrialSimulation of an epidural test dose with intravenous epinephrine in sevoflurane-anesthetized children.
An epidural test dose containing small doses of epinephrine does not produce a reliable increase in heart rate (HR) in children under halothane anesthesia. Because sevoflurane is increasingly used in clinical practice, we designed the present study to determine the hemodynamic responses to, and efficacy of, a simulated IV test dose containing a small dose of epinephrine in sevoflurane-anesthetized children. Sixty ASA physical status I infants and children (4.1 +/- 2.5 yr) undergoing elective minor surgeries were studied during 1.0 minimum alveolar anesthetic concentration of sevoflurane and 60% nitrous oxide in oxygen. The patients were randomly assigned to receive either saline (n = 15), a test dose consisting of 1% lidocaine (0.1 mL/kg) with 1:200,000 epinephrine (0.5 microg/kg, n = 15), atropine 0.01 mg/kg followed 5 min later by saline (n = 15), or atropine followed by the test dose (n = 15) via a peripheral vein to simulate intravascular injection of the epidural test dose. HR and systolic blood pressure were recorded every 15 and 30 s, respectively. The test dose increased the HR from 15 to 60 s and from 15 to 90 s without and with atropine, respectively. Mean maximum increases in HR were similar with and without atropine (21 +/- 8 and 22 +/- 6 bpm, respectively). Of 15 children, 7 and 5 developed HR changes < 20 bpm after the test dose with and without atropine, respectively, whereas all children who received saline had an increase in HR < 20 bpm. No dysrhythmia occurred during the study. Our results indicate that an epidural test dose containing epinephrine is unreliable based on the conventional HR criterion (positive if > or = 20 bpm increase), but reliable on the modified HR criterion (positive if > or = 10 bpm increase) in children anesthetized with sevoflurane. I.v. atropine before the test dose injection did not improve the efficacy based on the conventional HR criterion. Because test doses of epinephrine-containing solution are used to determine whether an epidural catheter is intravascular, it is important to define the optimal test dose under sevoflurane anesthesia. ⋯ We found that during sevoflurane anesthesia in children, a heart rate increase > or = 10 bpm and a systolic blood pressure increase > or = 15 mm Hg, when preceded by atropine, may be reliable indicators for detecting intravascular injection.
-
Uptake of inhaled anesthetics may be measured as the amount of anesthetic infused to maintain a constant alveolar concentration of anesthetic. This method assumes that the patient absorbs all of the infused anesthetic, and that none is lost to circuit components. Using a standard anesthetic circuit with a 3-L rebreathing bag simulating the lungs, and simulating metabolism by input of carbon dioxide, we tested this assumption for halothane, isoflurane, and sevoflurane. Our results suggest that after washin of anesthetic sufficient to eliminate a material difference between inspired and end-tidal anesthetic, washin to other parts of the circuit (probably the ventilator) and absorbent (soda lime) continued to remove anesthetic for up to 15 min. From 30 min to 180 min of anesthetic administration, circuit components absorbed trivial amounts of isoflurane (12 +/- 13 mL vapor at 1.5 minimum alveolar anesthetic concentration, slightly more sevoflurane (39 +/- 15 mL), and still more halothane (64 +/- 9 mL). During this time, absorbent degraded sevoflurane (321 +/- 31 mL absorbed by circuit components and degraded by soda lime). The amount degraded increased with increasing input of carbon dioxide (e.g., the 321 +/- 31 mL increased to 508 +/- 48 mL when carbon dioxide input increased from 250 mL/min to 500 mL/min). Measurement of anesthetic uptake as a function of the amount of anesthetic infused must account for these findings. ⋯ Systems that deliver inhaled anesthetics may also remove the anesthetic. Initially, anesthetics may diffuse into delivery components and the interstices of material used to absorb carbon dioxide. Later, absorbents may degrade some anesthetics (e.g., sevoflurane). Such losses may compromise measurements of anesthetic uptake.
-
Anesthesia and analgesia · May 1998
Randomized Controlled Trial Clinical TrialPremedication with fentanyl and midazolam decreases the reliability of intravenous lidocaine test dose.
This study was performed to determine whether premedication with midazolam and fentanyl prevents reliable detection of an i.v. lidocaine test dose. Thirty ASA physical status I or II patients received either 3 mL of saline or 1.5 mg of midazolam (1.5 mL) plus 75 microg of fentanyl (1.5 mL) i.v. in a randomized, double-blind fashion. Five minutes later, lidocaine 1 mg/kg was injected i.v. At 1.5 min before and every minute after lidocaine administration, each subject was questioned regarding the presence of four symptoms of systemic lidocaine toxicity. Any new tinnitus, perioral numbness, metallic taste, or light-headedness within 5 min after lidocaine administration was considered a positive response. All 15 patients in the saline group (100% sensitivity) had a positive response to i.v. lidocaine, but only 9 of 15 patients in the sedation group had a positive response (60% sensitivity; P = 0.017). We conclude that midazolam and fentanyl premedication decreases the reliability of subjective detection of i.v. lidocaine. ⋯ Anesthesiologists often rely on subjective symptoms to prevent local anesthetic toxicity while performing regional anesthesia. Sedatives are often administered during the administration of regional anesthesia. This study demonstrates that typical sedation decreases the reliability of detection of local anesthetic toxicity by subjective symptoms.
-
Anesthesia and analgesia · May 1998
Randomized Controlled Trial Comparative Study Clinical TrialA comparison of patient-controlled analgesia with lornoxicam versus morphine in patients undergoing lumbar disk surgery.
The analgesic efficacy and tolerability of lornoxicam (Xefo; Nycomed Pharma A/S, Roskilde, Denmark), a new nonsteroidal antiinflammatory drug, was compared with that of morphine in a double-blind, randomized, parallel-group study of 96 patients with at least moderate pain after lumbar microsurgical discectomy. Both drugs were administered i.v. via a patient-controlled analgesia (PCA) for up to 24 h postoperatively. Efficacy was assessed by comparing mean hourly pain intensity differences, mean hourly pain relief, and total pain relief (TOTPAR) values derived from a 5-point verbal rating scores of pain intensity and pain relief at several time points over 24 h. Of 79 patients included in a per-protocol analysis, statistically significant equivalence of lornoxicam and morphine was shown by TOTPAR values of 31.6 and 28.9, respectively (P = 0.048). Trends toward slightly faster onset of analgesia with morphine and slightly greater PCA demands with lornoxicam were observed initially, which may partly have been due to a higher baseline pain intensity in the lornoxicam group. Lornoxicam caused fewer adverse events than morphine (21.7% vs 38.0% of patients, respectively), most of which were mild or moderate in severity. These results suggest that lornoxicam is an alternative to morphine when administered by PCA for the treatment of moderate to severe postoperative pain. ⋯ After surgery for lumbar disk disease, patients obtained statistically equivalent pain relief with lornoxicam and morphine when administered by patient-controlled analgesia. However, lornoxicam was associated with a lower incidence of adverse events. This study suggests that lornoxicam provides an alternative to morphine for the treatment of postoperative pain.